Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Adagene of Suzhou Files for $125 Million US IPO

publication date: Jan 21, 2021

Adagene, a Suzhou immunotherapy company, plans to raise up to $125 million in a US IPO on the NASDAQ Exchange. The company uses a computational AI-based discovery platform that studies the motion of proteins and their dynamic interactions to discover novel epitopes of drug targets, differentiating Adagene's candidates. It has novel antibodies in China and US trials that target CD137 in advanced solid tumors and non-Hodgkin's lymphoma, and. a masked anti-CTLA-4 mAb engineered for better safety by avoiding off-target activation. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital